Prostate Cancer: PF-06821497 with Enzalutamide

We are studying a new treatment combining PF-06821497 with enzalutamide for men with advanced prostate cancer previously treated with abiraterone. The goal is to see if this combination can improve survival and reduce tumor activity compared to standard therapies.

6-12 months Confirmation phase (III)No Placebo Cost Reimbursement Partially Remote Investigational Medicines Oral InjectionOncologyUrology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Minox 5

Minox 5 is a medicine you apply to the scalp to help regrow hair and slow hair loss from pattern baldness.

Prednisolone Eg

Prednisolone Eg is a steroid medicine used to reduce swelling and treat allergies, asthma attacks, and certain immune system conditions.

Xtandi

Xtandi is a medicine used to treat prostate cancer.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Dexamethasone

Dexamethasone is a steroid that reduces inflammation and suppresses the immune system to treat allergic, inflammatory, and autoimmune conditions.

Docetaxel

Docetaxel is a chemotherapy substance used to treat various cancers by stopping cancer cells from dividing.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

PF-06821497

Dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(r)-methoxy(oxetan-3-yl)methyl]-3

Dihydroisoquinolinone

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Adelcort®

Agrocia

Alocutan

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

University Hospital Olomouc

Department of Oncology

Olomouc, Czechia

Multiscan s.r.o.

Oncology

Pardubice, Czechia

Fakultni Nemocnice Kralovske Vinohrady

Oncology

Prague, Czechia

Sponsor: Pfizer Inc.

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.